Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma.

Blood neoplasia·2026

Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026

Same author

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

JAMA oncology·2026

Same author

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025

Same author

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Blood advances·2025

Search research articles

Related Experiment Video

Updated: Jul 2, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Management of relapsed diffuse large B-cell lymphoma.

Vaishalee Padgaonkar Kenkre¹, Sonali M Smith

¹Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637, USA.

Current Oncology Reports

|August 19, 2008

Summary

Many diffuse large B-cell lymphoma patients relapse after initial treatment. This review focuses on improving outcomes for relapsed disease using novel stem cell transplant strategies and peritransplant therapies.

Related Experiment Videos

Last Updated: Jul 2, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Area of Science:

Hematology
Oncology
Stem Cell Transplantation

Background:

Diffuse large B-cell lymphoma (DLBCL) frequently relapses despite effective first-line treatments.
Autologous stem cell transplantation (ASCT) is effective for relapsed DLBCL but benefits are limited to chemosensitive, low-risk patients.
New strategies are needed to improve outcomes for patients with relapsed or refractory DLBCL.

Purpose of the Study:

To review the current management of relapsed diffuse large B-cell lymphoma.
To highlight emerging peritransplant therapies aimed at improving outcomes after stem cell transplantation for relapsed DLBCL.
To discuss the potential of allogeneic stem cell transplantation in relapsed DLBCL.

Main Methods:

Review of current literature on relapsed diffuse large B-cell lymphoma management.
Emphasis on advancements in autologous and allogeneic stem cell transplantation.
Exploration of novel salvage regimens, radioimmunotherapy, and post-transplant strategies.

Main Results:

Autologous stem cell transplantation shows efficacy in select relapsed DLBCL patients.
Ongoing research focuses on enhancing salvage regimens and preparative strategies.
Post-transplant treatments aim to eradicate minimal residual disease for improved survival.

Conclusions:

Improving outcomes for relapsed DLBCL requires novel peritransplant approaches.
Further research is needed to optimize allogeneic stem cell transplantation for DLBCL.
Optimizing stem cell transplantation is key to managing relapsed diffuse large B-cell lymphoma.